Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings

EA Croonen, WM Nillesen, KE Stuurman, Grietje Oudesluijs, IMBM van de Laar, L Martens, C Ockeloen, IB Mathijssen, M Schepens, M Ruiterkamp-Versteeg, H Scheffer, BHW Faas, I van der Burgt, HG Yntema

Research output: Contribution to journalArticleAcademicpeer-review

92 Citations (Scopus)


In recent studies on prenatal testing for Noonan syndrome (NS) in fetuses with an increased nuchal translucency (NT) and a normal karyotype, mutations have been reported in 9-16% of cases. In this study, DNA of 75 fetuses with a normal karyotype and abnormal ultrasound findings was tested in a diagnostic setting for mutations in (a subset of) the four most commonly mutated NS genes. A de novo mutation in either PTPN11, KRAS or RAF1 was detected in 13 fetuses (17.3%). Ultrasound findings were increased NT, distended jugular lymphatic sacs (JLS), hydrothorax, renal anomalies, polyhydramnios, cystic hygroma, cardiac anomalies, hydrops fetalis and ascites. A second group, consisting of anonymized DNA of 60 other fetuses with sonographic abnormalities, was tested for mutations in 10 NS genes. In this group, five possible pathogenic mutations have been identified (in PTPN11 (n = 2), RAF1, BRAF and MAP2K1 (each n = 1)). We recommend prenatal testing of PTPN11, KRAS and RAF1 in pregnancies with an increased NT and at least one of the following additional features: polyhydramnios, hydrops fetalis, renal anomalies, distended JLS, hydrothorax, cardiac anomalies, cystic hygroma and ascites. If possible, mutation analysis of BRAF and MAP2K1 should be considered.
Original languageUndefined/Unknown
Pages (from-to)936-942
Number of pages7
JournalEuropean Journal of Human Genetics
Issue number9
Publication statusPublished - 2013

Research programs

  • EMC MGC-02-96-01

Cite this